On December 13, 2024, Kate Mckinley, Chief Business Officer at Rani Therapeutics Holdings Inc, purchased 17,960 shares of the company. Following this transaction, the insider now owns a total of 17,960 shares. The transaction details can be found in the SEC Filing.
Rani Therapeutics Holdings Inc (RANI, Financial) is a clinical-stage biotherapeutics company focused on developing technologies to convert injectable biologics into oral formulations. The company's innovative approach aims to improve patient compliance and expand the market for biologics.
The insider's recent purchase is part of a broader trend within the company. Over the past year, there have been two insider buys and one insider sell. Kate Mckinley has been active in the market, purchasing a total of 17,960 shares and selling none during this period.
Shares of Rani Therapeutics Holdings Inc were trading at $1.67 each on the day of the insider's purchase, resulting in a market cap of $52.962 million for the company.
For investors, insider buying can be a signal of confidence in the company's future prospects. However, it is essential to consider other factors such as the company's GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when evaluating the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
